Swiss pharmaceutical giant Roche said on April 16 sales had soared 7% to 11.6 billion francs (US$ 10.13 billion) in the first quarter of 2009, outstripping the global market.
Sales at its pharmaceutical division grew 8% to 9.21 billion francs, driven by its oncology, inflammation and ophthalmology portfolios.
Sales at its diagnostics division also rose 3% to 2.36 billion francs.
"Sales in both divisions continued to grow significantly faster than their respective markets. We are therefore confident that we can achieve our full-year targets, said Roche chief executive Severin Schwan.
He added that the group would update its full-year outlook when it reported its first-half results in July to include the impact of the group's buyout of U.S. biotechnology unit Genentech. Roche last month agreed to pay $46.8 billion to take full control of Genentech.
Copyright Agence France-Presse, 2009
About the Author
Agence France-Presse
Copyright Agence France-Presse, 2002-2025. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.